메뉴 건너뛰기




Volumn 13, Issue 3, 2008, Pages 11-18

Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring

Author keywords

Corticosteroids; Cyclosporine A; Drug interactions; Everolimus; Mycophenolate mofetil; Mycophenolic acid; Sirolimus; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

ANTIMITOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A5; DRUG METABOLITE; EVEROLIMUS; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; CYCLOSPORIN; DRUG DERIVATIVE;

EID: 58749088941     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (54)

References (50)
  • 2
    • 0033014930 scopus 로고    scopus 로고
    • Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
    • Shipkova M, Armstrong VW, Wieland E et al: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol, 1999; 126(5): 1075-82
    • (1999) Br J Pharmacol , vol.126 , Issue.5 , pp. 1075-1082
    • Shipkova, M.1    Armstrong, V.W.2    Wieland, E.3
  • 3
    • 0035079669 scopus 로고    scopus 로고
    • Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes
    • Shipkova M, Strassburg CP, Braun F et al: Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol, 2001; 132: 1027-34
    • (2001) Br J Pharmacol , vol.132 , pp. 1027-1034
    • Shipkova, M.1    Strassburg, C.P.2    Braun, F.3
  • 4
    • 2442716361 scopus 로고    scopus 로고
    • Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats
    • Kobayashi M, Saitoh H, Kobayashi M et al: Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats. J Pharmacol Exper Ther, 2004; 309: 1029-35
    • (2004) J Pharmacol Exper Ther , vol.309 , pp. 1029-1035
    • Kobayashi, M.1    Saitoh, H.2    Kobayashi, M.3
  • 5
    • 0035189304 scopus 로고    scopus 로고
    • Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: Preliminary report
    • Shipkova M, Armstrong VW, Kuypers D et al: Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit, 2001; 23(6): 717-21
    • (2001) Ther Drug Monit , vol.23 , Issue.6 , pp. 717-721
    • Shipkova, M.1    Armstrong, V.W.2    Kuypers, D.3
  • 6
    • 0038298273 scopus 로고    scopus 로고
    • Longterm changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients
    • Kuypers DRJ, Claes K, Evenepoel P et al: Longterm changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol, 2003; 43(8): 866-80
    • (2003) J Clin Pharmacol , vol.43 , Issue.8 , pp. 866-880
    • Kuypers, D.R.J.1    Claes, K.2    Evenepoel, P.3
  • 7
    • 34547876119 scopus 로고    scopus 로고
    • The impact of renal allograft function on exposure and elimination of mycophenolic acid (mpa) and its metabolite mpa 7-o-glucuronide
    • Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR: The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. Transplantation, 2007; 84(3): 362-73
    • (2007) Transplantation , vol.84 , Issue.3 , pp. 362-373
    • Naesens, M.1    de Loor, H.2    Vanrenterghem, Y.3    Kuypers, D.R.4
  • 8
    • 2542590879 scopus 로고    scopus 로고
    • Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia
    • Atcheson B, Taylor P, Kirkpatrick C et al: Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit, 2004; 26(3): 284-86
    • (2004) Ther Drug Monit , vol.26 , Issue.3 , pp. 284-286
    • Atcheson, B.1    Taylor, P.2    Kirkpatrick, C.3
  • 9
    • 25844525727 scopus 로고    scopus 로고
    • The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region singlenucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
    • Kuypers DRJ, Naesens M, Vermeire S et al: The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region singlenucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther, 2005; 78: 351-61
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 351-361
    • Kuypers, D.R.J.1    Naesens, M.2    Vermeire, S.3
  • 10
    • 33750346955 scopus 로고    scopus 로고
    • Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients
    • Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y: Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients. Transplantation, 2006; 82(8): 1074-84
    • (2006) Transplantation , vol.82 , Issue.8 , pp. 1074-1084
    • Naesens, M.1    Kuypers, D.R.2    Verbeke, K.3    Vanrenterghem, Y.4
  • 11
    • 0030670814 scopus 로고    scopus 로고
    • Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
    • Zucker K, Rosen A, Tsaroucha A et al: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol, 1997; 5(3): 225-32
    • (1997) Transplant Immunol , vol.5 , Issue.3 , pp. 225-232
    • Zucker, K.1    Rosen, A.2    Tsaroucha, A.3
  • 12
    • 0035086852 scopus 로고    scopus 로고
    • Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
    • van Gelder T, Klupp J, Barten MJ et al: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit, 2001; 23(2): 119-28
    • (2001) Ther Drug Monit , vol.23 , Issue.2 , pp. 119-128
    • van Gelder, T.1    Klupp, J.2    Barten, M.J.3
  • 13
    • 17644377916 scopus 로고    scopus 로고
    • Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2
    • Hesselink DA, van Hest RM, Mathot RAA et al: Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am Journal Transplant, 2005; 5(5): 987-95
    • (2005) Am Journal Transplant , vol.5 , Issue.5 , pp. 987-995
    • Hesselink, D.A.1    van Hest, R.M.2    Mathot, R.A.A.3
  • 14
    • 31444448077 scopus 로고    scopus 로고
    • Role of Mrp2 in the hepatic disposition of mycophenolic acid: Effect of cyclosporin
    • Westley IS, Brogan LR, Morris RG et al: Role of Mrp2 in the hepatic disposition of mycophenolic acid: effect of cyclosporin. Drug Metab Dispos, 2006; 34(2): 261-266
    • (2006) Drug Metab Dispos , vol.34 , Issue.2 , pp. 261-266
    • Westley, I.S.1    Brogan, L.R.2    Morris, R.G.3
  • 15
    • 22244431879 scopus 로고    scopus 로고
    • Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium
    • Bruce Kaplan, Herwig-Ulf Meier-Kriesche, Paula Minnick, Marie-Claude Bastien, Romain Sechaud, Ching-Ming Yeh, Sebastien Balez, Franck Picard, Robert Schmouder: Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant, 2005; 19(4): 551-558
    • (2005) Clin Transplant , vol.19 , Issue.4 , pp. 551-558
    • Kaplan, B.1    Meier-Kriesche, H.-U.2    Minnick, P.3    Marie-Claude, B.4    Sechaud, R.5    Ching-Ming, Y.6    Balez, S.7    Picard, F.8    Schmouder, R.9
  • 16
    • 77956281242 scopus 로고    scopus 로고
    • Pharmacokinetics of mycophenolate mofetil at 12 months in the presence and absence of cyclosporine
    • (Abstract)
    • DRJ Kuypers, H Ekberg, J Grinyo et al: Pharmacokinetics of mycophenolate mofetil at 12 months in the presence and absence of cyclosporine. Transplant Int, 2005; 18(Suppl.1): 50 (Abstract)
    • (2005) Transplant Int , vol.18 , Issue.SUPPL. 1 , pp. 50
    • Kuypers, D.R.J.1    Ekberg, H.2    Grinyo, J.3
  • 17
    • 33745957413 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of mycophenolate mofetil in transplantation
    • van Gelder T, Le Meur Y, Shaw LM et al: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit, 2006; 28: 145-54
    • (2006) Ther Drug Monit , vol.28 , pp. 145-154
    • van Gelder, T.1    Le, M.Y.2    Shaw, L.M.3
  • 18
    • 35248860066 scopus 로고    scopus 로고
    • For the FDCC Study Group: A prospective, randomized study comparing fixed dose versus concentration controlled MMF regimens for de novo patients following renal transplantation (The FDCC trial)
    • (Abstract)
    • van Gelder T, Tedesco-Silva H, de Fijter H et al: for the FDCC Study Group: A prospective, randomized study comparing fi xed dose versus concentration controlled MMF regimens for de novo patients following renal transplantation (The FDCC trial). Am J Transplant, 2006; 6(Suppl.2): 343 (Abstract)
    • (2006) Am J Transplant , vol.6 , Issue.SUPPL. 2 , pp. 343
    • van Gelder, T.1    Tedesco-Silva, H.2    de Fijter, H.3    et al4
  • 19
    • 36249004730 scopus 로고    scopus 로고
    • Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy
    • (Abstract)
    • Grinyo J, Ekberg H, Oppenheimer F et al: Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy. Am J Transplant, 2006; 6(Suppl.2): 345 (Abstract)
    • (2006) Am J Transplant , vol.6 , Issue.SUPPL. 2 , pp. 345
    • Grinyo, J.1    Ekberg, H.2    Oppenheimer, F.3
  • 20
    • 35248839494 scopus 로고    scopus 로고
    • Individualized mycophenolate mofetil dosing based on drug exposure signifi cantly improves patient outcomes after renal transplantation
    • Le Meur Y, Büchler M, Thierry A et al: Individualized mycophenolate mofetil dosing based on drug exposure signifi cantly improves patient outcomes after renal transplantation. Am J Transplant, 2007; 7: 2496-503
    • (2007) Am J Transplant , vol.7 , pp. 2496-2503
    • Le, M.Y.1    Büchler, M.2    Thierry, A.3
  • 21
    • 0033023263 scopus 로고    scopus 로고
    • Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
    • Zucker K, Tsaroucha A, Olson L et al: Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit, 1999; 21: 35-43
    • (1999) Ther Drug Monit , vol.21 , pp. 35-43
    • Zucker, K.1    Tsaroucha, A.2    Olson, L.3
  • 22
    • 33644824716 scopus 로고    scopus 로고
    • Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation
    • Cattaneo D, Merlini S, Zenoni S et al: Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. Am J Transplant, 2005; 5(12): 2937-44
    • (2005) Am J Transplant , vol.5 , Issue.12 , pp. 2937-2944
    • Cattaneo, D.1    Merlini, S.2    Zenoni, S.3
  • 23
    • 36849071973 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients
    • Pescovitz MD, Vincenti F, Hart M et al: Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol, 2007; 64(6): 758-71
    • (2007) Br J Clin Pharmacol , vol.64 , Issue.6 , pp. 758-771
    • Pescovitz, M.D.1    Vincenti, F.2    Hart, M.3
  • 24
    • 4344686731 scopus 로고    scopus 로고
    • Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs
    • Renders L, Steinbach R, Valerius T et al: Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res, 2004; 27(3): 181-85
    • (2004) Kidney Blood Press Res , vol.27 , Issue.3 , pp. 181-185
    • Renders, L.1    Steinbach, R.2    Valerius, T.3
  • 25
    • 0036424769 scopus 로고    scopus 로고
    • Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
    • Cattaneo D, Perico N, Gaspari F et al: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int, 2002; 62(3): 1060-67
    • (2002) Kidney Int , vol.62 , Issue.3 , pp. 1060-1067
    • Cattaneo, D.1    Perico, N.2    Gaspari, F.3
  • 26
    • 0029827815 scopus 로고    scopus 로고
    • Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
    • Stepkowski SM, Napoli KL, Wang ME et al: Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation, 1996; 62(7): 986-94
    • (1996) Transplantation , vol.62 , Issue.7 , pp. 986-994
    • Stepkowski, S.M.1    Napoli, K.L.2    Wang, M.E.3
  • 27
    • 0035042276 scopus 로고    scopus 로고
    • Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations
    • Podder H, Stepkowski SM, Napoli KL et al: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol, 2001; 12: 1059-71
    • (2001) J Am Soc Nephrol , vol.12 , pp. 1059-1071
    • Podder, H.1    Stepkowski, S.M.2    Napoli, K.L.3
  • 28
    • 0031958040 scopus 로고    scopus 로고
    • Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration in the rat: Evidence for pharmacokinetic interactions
    • Napoli KL, Wang ME, Stepkowski SM et al: Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration in the rat: evidence for pharmacokinetic interactions. Ther Drug Monit, 1998; 20(2): 123-33
    • (1998) Ther Drug Monit , vol.20 , Issue.2 , pp. 123-133
    • Napoli, K.L.1    Wang, M.E.2    Stepkowski, S.M.3
  • 29
    • 33746530366 scopus 로고    scopus 로고
    • The Rapamune US Study Group: Efficacy of sirolimus compare with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
    • Kahan BD The Rapamune US Study Group: Efficacy of sirolimus compare with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet, 2000; 356: 194-202
    • (2000) Lancet , vol.356 , pp. 194-202
    • Kahan, B.D.1
  • 30
    • 0035956745 scopus 로고    scopus 로고
    • The RAPAMUNE Global Study Group: A worldwide, phase III, randomised, controlled, safety and effi cacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
    • MacDonald AS The RAPAMUNE Global Study Group: A worldwide, phase III, randomised, controlled, safety and effi cacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation, 2001; 71(2): 271-80
    • (2001) Transplantation , vol.71 , Issue.2 , pp. 271-280
    • MacDonald, A.S.1
  • 31
    • 3943072739 scopus 로고    scopus 로고
    • 156 Study Group: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, openlabel study
    • Nashan B, Curtis J, Ponticelli C et al: 156 Study Group: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, openlabel study. Transplantation, 2004; 78(9): 1332-40
    • (2004) Transplantation , vol.78 , Issue.9 , pp. 1332-1340
    • Nashan, B.1    Curtis, J.2    Ponticelli, C.3
  • 32
    • 0037961745 scopus 로고    scopus 로고
    • Fixed-dose sirolimus with reduced dose calcineurin inhibitor: The university of Colorado experience
    • Wiseman AC, Kam I, Christians U et al: Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the university of Colorado experience. Transplant Proc, 2003; 35(Suppl.3A): 122S-24S
    • (2003) Transplant Proc , vol.35 , Issue.SUPPL. 3A , pp. 122-124
    • Wiseman, A.C.1    Kam, I.2    Christians, U.3
  • 33
    • 0033567982 scopus 로고    scopus 로고
    • Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
    • Hong JC, Kahan BD: Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation, 1999; 68(5): 701-4
    • (1999) Transplantation , vol.68 , Issue.5 , pp. 701-704
    • Hong, J.C.1    Kahan, B.D.2
  • 34
    • 0036901716 scopus 로고    scopus 로고
    • Basiliximabsirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors
    • Langer RM, Hong DM, Katz SM et al: Basiliximabsirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors. Transplant Proc, 2002; 34: 3162-64
    • (2002) Transplant Proc , vol.34 , pp. 3162-3164
    • Langer, R.M.1    Hong, D.M.2    Katz, S.M.3
  • 35
    • 0035884710 scopus 로고    scopus 로고
    • Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure
    • Johnson RW, Kreis H, Oberbauer R et al: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation, 2001; 72(5): 777-86
    • (2001) Transplantation , vol.72 , Issue.5 , pp. 777-786
    • Johnson, R.W.1    Kreis, H.2    Oberbauer, R.3
  • 36
    • 16244378141 scopus 로고    scopus 로고
    • The B251 Study Group: Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study
    • Lorber M, Mulgaonkar S, Butt KMH et al: the B251 Study Group: Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study. Transplantation, 2005; 80(2): 244-52
    • (2005) Transplantation , vol.80 , Issue.2 , pp. 244-252
    • Lorber, M.1    Mulgaonkar, S.2    Butt, K.M.H.3
  • 37
    • 33644696712 scopus 로고    scopus 로고
    • For the RAD B201 Study Group: Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients
    • Vítko Š, Margreiter R, Weimar W et al: for the RAD B201 Study Group: Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients. Am J Transplant, 2005; 5(10): 2521-30
    • (2005) Am J Transplant , vol.5 , Issue.10 , pp. 2521-2530
    • Vítko, S.1    Margreiter, R.2    Weimar, W.3
  • 38
    • 5644239801 scopus 로고    scopus 로고
    • Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats
    • Konishi H, Sumi M, Shibata N et al: Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharmacy Pharmacol, 2004; 56: 1259-66
    • (2004) J Pharmacy Pharmacol , vol.56 , pp. 1259-1266
    • Konishi, H.1    Sumi, M.2    Shibata, N.3
  • 39
    • 33748539303 scopus 로고    scopus 로고
    • Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporine A absorption, and effect of dexamethasone in small intestine of mice
    • Jin M, Shimada T, Yokogawa K et al: Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporine A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol, 2006; 72(8): 1042-50
    • (2006) Biochem Pharmacol , vol.72 , Issue.8 , pp. 1042-1050
    • Jin, M.1    Shimada, T.2    Yokogawa, K.3
  • 40
    • 0242558148 scopus 로고    scopus 로고
    • Increase in tacrolimus trough levels after steroid withdrawal
    • van Duijnhoven EM et al: Increase in tacrolimus trough levels after steroid withdrawal. Transplant Int, 2003; 16: 721-25
    • (2003) Transplant Int , vol.16 , pp. 721-725
    • van Duijnhoven, E.M.1
  • 41
    • 0041317355 scopus 로고    scopus 로고
    • Tacrolimus dose requirement in renal transplant recipients is signifi cantly higher when used in combination with corticosteroids
    • Hesselink DA, Ngyuen H, Wabbijn M et al: Tacrolimus dose requirement in renal transplant recipients is signifi cantly higher when used in combination with corticosteroids. Br J Clin Pharmacol, 2003; 56(3): 327-30
    • (2003) Br J Clin Pharmacol , vol.56 , Issue.3 , pp. 327-330
    • Hesselink, D.A.1    Ngyuen, H.2    Wabbijn, M.3
  • 42
    • 0036851317 scopus 로고    scopus 로고
    • Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after highdose steroid therapy
    • Shimada T et al: Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after highdose steroid therapy. Transplantation, 2002; 74: 1419-24
    • (2002) Transplantation , vol.74 , pp. 1419-1424
    • Shimada, T.1
  • 43
    • 47949092525 scopus 로고    scopus 로고
    • The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans
    • Epub ahead of print
    • Roberts P, Rollins K, Kashuba A et al: The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos, 2008; Epub ahead of print
    • (2008) Drug Metab Dispos
    • Roberts, P.1    Rollins, K.2    Kashuba, A.3
  • 44
    • 0036001229 scopus 로고    scopus 로고
    • A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration
    • McAlister VC, Mahalati K, Peltekian KM et al: A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit, 2002; 24: 346-50
    • (2002) Ther Drug Monit , vol.24 , pp. 346-350
    • McAlister, V.C.1    Mahalati, K.2    Peltekian, K.M.3
  • 45
    • 0042266823 scopus 로고    scopus 로고
    • Longterm pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients
    • Kuypers DRJ, Claes K, Evenepoel P et al: Longterm pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit, 2003; 25(4): 447-51
    • (2003) Ther Drug Monit , vol.25 , Issue.4 , pp. 447-451
    • Kuypers, D.R.J.1    Claes, K.2    Evenepoel, P.3
  • 46
    • 0038684549 scopus 로고    scopus 로고
    • Pharmacokinetics of tacrolimus-based combination therapies
    • Undre NA: Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant, 2003; 18(Suppl.1): 12-15
    • (2003) Nephrol Dial Transplant , vol.18 , Issue.SUPPL. 1 , pp. 12-15
    • Undre, N.A.1
  • 47
    • 38549132528 scopus 로고    scopus 로고
    • Everolimus exposure in cardiac transplant recipients is infl uenced by concomitant alcineurin inhibitor
    • Brandhorst G, Tenderich G, Zittermann A et al: Everolimus exposure in cardiac transplant recipients is infl uenced by concomitant alcineurin inhibitor. Ther Drug Monit, 2008; 30(1): 113-16
    • (2008) Ther Drug Monit , vol.30 , Issue.1 , pp. 113-116
    • Brandhorst, G.1    Tenderich, G.2    Zittermann, A.3
  • 48
    • 10744220677 scopus 로고    scopus 로고
    • A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year
    • Ciancio G, Burke GW, Gaynor JJ et al: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation, 2004; 77(2): 244-51
    • (2004) Transplantation , vol.77 , Issue.2 , pp. 244-251
    • Ciancio, G.1    Burke, G.W.2    Gaynor, J.J.3
  • 49
    • 18044379147 scopus 로고    scopus 로고
    • Effects of calcineurininhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients
    • Wu F, Tsai M, Chen R et al: Effects of calcineurininhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy, 2005; 25(5): 646-53
    • (2005) Pharmacotherapy , vol.25 , Issue.5 , pp. 646-653
    • Wu, F.1    Tsai, M.2    Chen, R.3
  • 50
    • 0030477754 scopus 로고    scopus 로고
    • Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants
    • Jusko W, Ferron G, Mis S et al: Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol, 1996; 36(12): 1100-1106
    • (1996) J Clin Pharmacol , vol.36 , Issue.12 , pp. 1100-1106
    • Jusko, W.1    Ferron, G.2    Mis, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.